Evidence map›Paper›PMID 40405288›Full record

ArticleCritical care (London, England)2025

First dose target attainment with extended infusion regimens of piperacillin and meropenem.

Gustaf Beijer, Maria Swartling, Elisabet I Nielsen, Olof Breuer, Christian G Giske, Erik Eliasson, Johan Petersson

Abstract read
In one paragraph

Article in Critical care (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gustaf BeijerMDK, Medical Unit of Clinical Pharmacology, Karolinska University Hospital, 141 86, Huddinge, Stockholm, Sweden. gustaf.beijer@regionstockholm.se.
Maria SwartlingDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Elisabet I NielsenDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Olof BreuerMDK, Medical Unit of Clinical Pharmacology, Karolinska University Hospital, 141 86, Huddinge, Stockholm, Sweden.
Christian G GiskeMDK, Medical Unit of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Erik EliassonMDK, Medical Unit of Clinical Pharmacology, Karolinska University Hospital, 141 86, Huddinge, Stockholm, Sweden.
Johan PeterssonFunction Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.

Funding

Region Stockholm ALF FoUI-974859VINNOVA 2018-03340, 2021-02699
6 · The paper itself

Abstract

backgroundStandard dosing regimens of meropenem and piperacillin-tazobactam frequently fail to achieve targeted plasma concentrations in critically ill patients. Extended or continuous regimens are often used to improve target attainment. Although prompt antibiotic initiation is a major determinant of survival, few studies have reported systemic concentrations early after treatment initiation. No prior study has reported concentrations immediately after the loading dose and first extended infusion. This study aimed to evaluate plasma target attainment during the first dosing interval with an extended infusion regimen in a general intensive care unit (ICU).

methodsAdult ICU patients were prospectively included in conjunction with the first administration of meropenem or piperacillin-tazobactam. Treatment was initiated with a 0.5 h loading dose immediately followed by a 3 h extended infusion; typically 4 + 4 g piperacillin or 1(- 2)g + 1(- 2)g meropenem, in line with the local ICU protocol. Patients requiring renal replacement therapy were excluded. Plasma concentrations were measured post-loading dose (C

resultsWe included 65 meropenem and 142 piperacillin measurements from 22 and 48 patients, respectively. Many patients (45% meropenem, 38% piperacillin) failed to reach 100% fT > MIC with the standard regimens used. Target non-attainment was associated with high estimated glomerular filtration rates (eGFR) and suspected augmented renal clearance (ARC). All meropenem patients that failed to reach target had eGFR > 90 mL/min/1.73 m

conclusionsDespite aggressive dosing, plasma concentrations often fail to reach 100% fT > MIC during the first dosing interval. Alternative regimens and early plasma concentration measurements followed by adaptive dose adjustments should be considered to improve target attainment.

Indexed as

Anti-Bacterial AgentsPiperacillinThienamycinsAdultAgedCritical IllnessDose-Response Relationship, DrugFemaleHumansInfusions, IntravenousIntensive Care UnitsMaleMeropenemMicrobial Sensitivity TestsMiddle AgedPenicillanic AcidAnti-Bacterial AgentsMeropenemPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationThienamycinsBeta-lactam antibioticsIntensive carePharmacodynamicsPharmacokineticsTherapeutic drug monitoring

Identifiers

PMID40405288
PMCPMC12096718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.